✦ LIBER ✦

Velnacrine for the treatment of Alzheimer's disease: A double-blind, placebo-controlled trial

✍ Scribed by F. P. Zemlan

Publisher: Springer
Year: 1996
Tongue: English
Weight: 805 KB
Volume: 103
Category: Article
ISSN: 1435-1463
DOI: 10.1007/bf01291795

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A double-blind, placebo-controlled singl

A double-blind, placebo-controlled single dose trial of intravenous flumazenil in Alzheimer's disease

✍ Lisa Templeton; Andrew Barker; Keith Wesnes; David Wilkinson 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB 👁 2 views

Benzodiazepine agonists have been shown to reduce cognitive functioning by producing attentional de®cits similar to those produced by muscarinic antagonists. It has therefore been postulated that benzodiazepine antagonists may improve cognitive function in patients with Alzheimer's disease by indire

A double-blind, placebo controlled, mult

A double-blind, placebo controlled, multicentre study of tacrine for alzheimer's disease

✍ Philip C. Wood; Professor C. Mark Castleden 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 527 KB

The present study was designed to determine whether oral tacrine (tetrahydroaminoacridine, THA) improves the symptoms of patients with mild to moderate Alzheimer's disease. The study was a multicentre, randomized doubleblind, placebo controlled, parallel group study with individual determination of

Sarizotan as a treatment for dyskinesias

Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial

✍ Christopher G. Goetz; Philippe Damier; Christine Hicking; Eugene Laska; Thomas M 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 1 views

## Abstract The objective of this study is to conduct a dose‐finding study of sarizotan in Parkinson's disease (PD) patients with dyskinesia to identify a safe dose and to identify a sensitive dyskinesia rating measure. Sarizotan is a novel compound with full 5‐HT~1A~ agonist properties and additio

Risperidone for psychosis of Alzheimer's

Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial

✍ Henry Brodaty; David Ames; John Snowdon; Michael Woodward; Jeff Kirwan; Roger Cl 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 2 views

## Objective: To evaluate the efficacy and safety of low-dose risperidone in treating psychosis of alzheimer's disease (ad) and mixed dementia (md) in a subset of nursing-home residents who had dementia and aggression and who were participating in a randomized placebo-controlled trial of risperidon

Treatment with simvastatin in normochole

Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial

✍ Mikael Simons; Frank Schwärzler; Dieter Lütjohann; Klaus Von Bergmann; Konrad Be 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease

✍ J. P. Wright; Dr. D. P. Jewell; R. Modigliani; H. Malchow 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB 👁 2 views

Olsalazine, consisting of two salicylate radicals linked by an azo-bond, is effective in the treatment of active ulcerative colitis. To test its effect in patients with mild to moderate attacks of Crohn's disease, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) des